Arctic Bioscience AS Rendement FCF

Que fait Arctic Bioscience AS ? Arctic Bioscience AS is a biotechnology company headquartered in Orsta, Norway, operating within the Health Care sector. The company focuses on the development, manufacturing, and marketing of marine ingredients derived from herring roe. It completed its initial public offering (IPO) on February 24, 2021. Arctic Bioscience aims to provide effective and healthy therapeutic solutions for individuals with autoimmune disorders through marine membrane lipids. The company is developing HRO350, an investigational drug candidate intended for the treatment of mild-to-moderate psoriasis. Its product portfolio includes Romega, a dietary supplement containing omega-3 fatty acids sourced from herring roe in capsule form, as well as herring caviar oil and herring caviar protein offered to business customers. The company operates through three subsidiaries: Arctic Nutrition AS, Romega AS, and Arctic Biopharma AS. Arctic Bioscience AS is listed on the Oslo Stock Exchange under the ticker symbol ABS.OL and holds the ISIN NO0010859580. The company's activities are centered around leveraging marine resources for health-related applications, with a focus on innovative biotechnology solutions for autoimmune conditions and skin health. Arctic Bioscience AS est l'une des entreprises les plus populaires sur Eulerpool.